Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3526841 | 0.87 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2KDM4EHSD17B10MAPT | |
| SCHEMBL9624571 | 0.87 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD | |
| SCHEMBL7532986 | 0.84 | ADRB3 (0.48) | ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD | |
| SCHEMBL10543746 | 0.84 | PYGL (0.53) | ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD | |
| SCHEMBL14389382 | 0.84 | KDM4E (0.70) | ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD | |
| SCHEMBL13719670 | 0.83 | KDM4E (0.46) | ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD | |
| SCHEMBL14038485 | 0.83 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD | |
| SCHEMBL7109004 | 0.83 | HTT (0.56) | ALDH1A1SMN1; SMN2KDM4EHPGDMAPT | |
| SCHEMBL1120778 | 0.81 | ADRB3 (0.46) | ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD | |
| SCHEMBL966589 | 0.81 | ADRB3 (0.58) | ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10072000-B2 | Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines | FERRER INTERNACIONAL, S.A. (ES) | 2018-09-11 | — | — | US | disclosed |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACTIONAL, S.A. (ES) | 2016-12-22 | — | — | US | disclosed |
| US-20130331401-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACTIONAL, S.A. (ES) | 2013-12-12 | — | — | US | disclosed |
| US-20130331610-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-12-12 | — | — | US | disclosed |
| US-8530482-B2 | Halogenated pyrazolo[1,5-A]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-09-10 | — | — | US | disclosed |
| EP-1899343-B1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INT (ES) | 2010-05-12 | — | — | EP | disclosed |
| US-20090111848-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2009-04-30 | — | — | US | disclosed |
| EP-1899343-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | Ferrer Internacional, S.A. (ES) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136530-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-28 | — | — | WO | disclosed |
| EP-1736475-A1 | Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-27 | — | — | EP | disclosed |
| EP-1254885-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE SECONDARY ALCOHOLS HAVING NITROGENOUS OR OXYGENIC FUNCTIONAL GROUPS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-1209150-A1 | PROCESSES FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-05-29 | — | — | EP | disclosed |
| EP-1195371-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-04-10 | — | — | EP | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
| WO-2002006232-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-1174425-A1 | NOVEL METHOD FOR MANUFACTURING TRICYCLIC AMINO ALCOHOL DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-01-23 | — | — | EP | disclosed |
| US-6187809-B1 | BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6172099-B1 | CARBAZOLE, DIBENZOFURAN, OR DIBENZOTHIOPHENE DERIVATIVES; DIETETICS, ANTIDIABETIC AGENTS; ANTILIPEMICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-01-09 | — | — | US | disclosed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331401-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | ALDH1A1 684/4885SMN1; SMN2 1345/4885KDM4E 1328/4885 |
| US-10072000-B2 | Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines | GABRA5, GABRA1, GABBR1 | ALDH1A1 502/4885SMN1; SMN2 1267/4885KDM4E 1019/4885 |
| US-20130331610-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | ALDH1A1 684/4885SMN1; SMN2 1345/4885KDM4E 1328/4885 |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | GABRA5, GABRA1, RYR1 | ALDH1A1 684/4885SMN1; SMN2 1345/4885KDM4E 1328/4885 |
| US-20090111848-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | ALDH1A1 684/4885SMN1; SMN2 1345/4885KDM4E 1328/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ALDH1A1 1091/4885SMN1; SMN2 3999/4885KDM4E 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.